Melanotan-1 and Melanotan-2 are not two strengths of one compound. One is a linear analogue of α-MSH with a modest set of substitutions; the other is a cyclic, shortened molecule with a substantially different receptor profile. The numbering suggests a sequence of versions. The chemistry suggests two different answers to the same design question, and the difference is selectivity.
What each one is
Both derive from α-melanocyte-stimulating hormone, a 13-residue peptide acting across the five melanocortin receptors.
Melanotan-1 — also called afamelanotide, and the name change matters because it has an approved clinical use under it — keeps the full 13-residue length with two substitutions: a D-amino acid at position 4 and a norleucine at position 7. Both are stability modifications. The receptor profile stays close to the parent hormone's, with a preference for MC1R.
Melanotan-2 is shorter, seven residues, and cyclic: a lactam bridge locks the backbone into a constrained ring. Cyclisation buys stability and, more importantly, fixes the molecule in a conformation. That conformation happens to be one several melanocortin receptors accept, so MT-2 is a broad agonist rather than a selective one.
| Melanotan-1 | Melanotan-2 | |
|---|---|---|
| Length | 13 residues | 7 residues |
| Shape | Linear | Cyclic lactam |
| Modifications | Nle⁴, D-Phe⁷ | Nle, D-Phe, plus the ring |
| Receptor profile | Preference for MC1R | Broad: MC1R, MC3R, MC4R, MC5R |
| Other name | Afamelanotide | None in clinical use |
Why does cyclisation change the receptor profile?
Because a linear peptide samples many conformations and a cyclic one does not. A flexible molecule can adapt its shape to each receptor it encounters, so binding is governed largely by sequence complementarity. Locking the backbone into a ring removes that flexibility: the molecule presents one arrangement of side chains, and every receptor either accepts it or does not. Constraint usually increases selectivity, which is the whole point of cyclising a peptide. In this case it did not — the locked conformation suits several melanocortin receptors at once, so MT-2 ended up broad. That is an instructive outcome rather than a failed design, and it is why receptor profiles have to be measured rather than predicted from structure. What closing a ring changes in general is its own subject.
Is Melanotan-2 more potent than Melanotan-1?
The question conflates potency with breadth, which is the most common error in reading these two. MT-2 engages more receptors; that is a different property from binding any one of them more tightly. At MC1R specifically the two are broadly comparable. What differs is that MT-2 also engages MC3R, MC4R and MC5R, which are expressed on different tissues and carry different signalling consequences. In an assay reading MC1R alone, the broader compound may well look no stronger — and in a whole-organism model the extra receptor activity is what separates them. Reading a receptor count as a potency ranking fails here the same way it does for the incretins.
What the D-amino acid and norleucine are doing
Both are stability modifications and both are visible in the name if you know the notation.
D-phenylalanine at position 7 replaces the natural L form with its mirror image. Proteases are stereospecific — they evolved to cleave L-amino acid chains — so a D residue at a cleavage site is not recognised. It also alters local backbone geometry, which can change receptor interaction, so the substitution is rarely purely about stability.
Norleucine at position 4 replaces methionine. Methionine's sulphur oxidises readily, and an oxidised methionine is a degradation product with a mass one oxygen heavier. Norleucine has a straight carbon chain of similar size and shape with no sulphur, so it fills the same space and cannot oxidise. Substituting it removes a degradation route entirely rather than slowing it — the same logic behind the non-natural residues used across engineered peptides.
Where does PT-141 fit?
It is a metabolite of Melanotan-2 that became a compound in its own right, which is an unusual lineage. Bremelanotide differs from MT-2 by the loss of the C-terminal amide group, and the change shifts its profile toward MC4R and away from MC1R. The three therefore form a gradient rather than a series of improvements: MT-1 weighted toward MC1R, MT-2 broad, PT-141 weighted toward MC4R. Choosing between them is a question about which receptor the work is aimed at, not which is newest.
Why does Melanotan-1 have a generic name and Melanotan-2 not?
Because an INN is assigned to a substance entering regulated development, and only MT-1 did. Afamelanotide has an approved clinical use in a narrow indication; MT-2 has no approved use anywhere. The naming asymmetry is therefore informative rather than cosmetic — it marks which of the two has been through a process that generated a regulatory evidence base. Naming systems answer different questions, and this is a case where the presence or absence of a generic name is itself a datum.
Handling
Both are more robust than their length suggests, for the same reason: the modifications that defeat proteases also make them less fragile in general. Both are water-soluble. Neither carries a free cysteine.
The one specific point is light. Melanocortin analogues contain tryptophan and, in MT-1, other photosensitive residues, and prolonged light exposure in solution can degrade them. Amber vials or foil, and minimising bench time for working solutions, is the whole of the precaution. Otherwise the ordinary rules apply: aliquot rather than repeatedly thaw, and record the reconstitution date and concentration at the moment they are made.
Does the cyclic structure make Melanotan-2 more stable in storage?
Against enzymes, yes; against chemistry, not especially. The lactam bridge removes the free termini that exopeptidases attack, which is a real stability gain in any system containing proteases. It does nothing about hydrolysis, oxidation or deamidation, which are chemical processes indifferent to shape. A cyclic peptide in a vial on a bench degrades by the same routes as a linear one, so the storage rules do not relax. Cyclisation is protection against biology, not against time.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
